How to Start a Menopause and HRT Telehealth Brand in 2026

Checked October 18, 2026. Prices are entry prices from the Telehealth Match database (our sister comparison site) unless noted.

Why now

On November 10, 2025, FDA began removing the boxed warnings on cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy. Labels now advise starting systemic therapy before age 60 or within 10 years of menopause. The first six relabeled products were approved on February 12, 2026 (FDA). The endometrial cancer boxed warning remains for systemic estrogen-alone products, so "FDA says HRT is safe" overstates it.

Hims expects menopause care to help its Hers brand scale toward $1 billion of revenue in 2026 (Hims Q3 2025 letter). Competition is coming fast.

The medications

• FDA-approved hormone therapy: estradiol (tablets, patches, gels, sprays, vaginal cream) and micronized progesterone, available as inexpensive generics.
• Non-hormonal options: Veozah (fezolinetant) and Lynkuet (elinzanetant, approved October 2025) for hot flashes.
• Compounded "bioidentical" hormones: not FDA-approved. The FDA-sponsored National Academies report advised restricting them to specific circumstances (NASEM, 2020). The Menopause Society says "patient preference alone should not be used to justify" them, and calls saliva, serum or urine hormone testing to set doses "unreliable" (Menopause Society, 2022).
• None are controlled, except testosterone prescribed to women (Schedule III), which falls under the DEA deadline (TRT guide).

Visits and labs

Async intake works where state law allows. Some menopause clinics choose video visits for a more personal experience; those cash visits ran $150–$249 in the database. Many brands offer hormone panels as an option, but the Menopause Society's position on dosing by hormone levels means labs should support the clinical picture, not drive the dose. Screen carefully for contraindications.

What brands charge, and what it costs

Cost of goods at Cost Plus Drugs (drug only, before the $5 fee and shipping):

FDA-approved generics are often cheaper for patients than compounded creams. One brand in the database prices estradiol tablets at $54 and progesterone at $39, against $89 for a compounded estrogen cream. The margin is in care, membership and bundles, such as menopause plus weight management, skin or hair.

Retention

No reliable public figure exists for first-year discontinuation of hormone therapy. Symptoms often last years: frequent hot flashes average 7.4 years, and about half of women see hot flashes return after stopping (Menopause Society). That supports long-term relationships if the care is good.

Claims to avoid

• "Natural," "safer," "identical to your body's hormones" or "FDA-approved" for compounded hormones.
• Saliva-test-based dosing.
• "FDA says HRT is safe." The label change removed specific warnings; it didn't remove all risk information.
• Any implication that a compounded product is the same as an approved drug (503A vs 503B).

Prescription ads on Meta and Google need LegitScript (our LegitScript guide).

Launch checklist

1. Choose a clinician network with clinicians experienced in menopause care (partners compared).
2. Lead with FDA-approved estradiol and progesterone. Offer compounded options only for documented needs, such as allergies or doses no approved product provides.
3. Price a membership for ongoing care, and consider bundles with weight, skin or hair.
4. Write education-first content: the label change is a big search topic, and accurate explainers earn trust.
5. Model your margin with the profit calculator.

---